PD-1 inhibitor immunotherapy for B cell lymphoma

Share This Post

A review written by Young, MD, Anderson Cancer Center, USA explained the application of PD-1 inhibitor immunotherapy in B-cell lymphoma. (Blood. Online version on November 8, 2017. doi: 10.1182 / blood-2017-07-740993.)

PD-1 immune checkpoint inhibitor treatment has shown significant efficacy in the treatment of advanced tumors including hematological malignancies. This review focuses on the clinical trials of PD-1 / PD-L1 expression and PD-1 inhibitor immunotherapy for B-cell lymphoma. Relapsed and refractory classic Hodgkin lymphoma usually have PD-1 positive tumor infiltrating T cells, 9p24 gene changes and high PD-L expression. In Phase I / II clinical trials, PD-1 inhibitors alone can bring an objective response rate (ORR) of 65% to 87% and continuous disease control. The median duration of remission in a phase II clinical trial was 16 months. In a phase I clinical trial, nivolumab was used to treat relapsed and refractory B-cell non-Hodgkin’s lymphoma including follicular lymphoma (CD4 positive T cells in the tumor usually have a large amount of PD-1 expression) and diffuse large B cell lymphoma Tumors (also express PD-1 and PD-L1 to varying degrees). Primary mediastinal large B-cell lymphoma often has 9p24 changes. In a phase II clinical trial, the ORR of pembrolizumab was 35%, the ORR of pembrolizumab was 0, and the treatment was Richter transformation. The ORR of chronic lymphocytic leukemia is 44%. Marginal zone lymphoma also has PD-1 expression, but mantle cell lymphoma does not. The review also describes the mechanism of PD-1 inhibitor immunotherapy, toxic reactions, predictive markers and combination treatment strategies.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer
Bladder cancer

Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

“Nogapendekin Alfa Inbakicept-PMLN, a novel immunotherapy, shows promise in treating bladder cancer when combined with BCG therapy. This innovative approach targets specific cancer markers while leveraging the immune system’s response, enhancing the efficacy of traditional treatments like BCG. Clinical trials reveal encouraging results, indicating improved patient outcomes and potential advancements in bladder cancer management. The synergy between Nogapendekin Alfa Inbakicept-PMLN and BCG heralds a new era in bladder cancer treatment.”

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy